

Obeticholic acid PK Fact Sheet

Prepared July 2019

Page 1 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Details


Generic Name Obeticholic acid

Trade Name Ocaliva®

Class PBC agents

Molecular Weight 420.63

Structure



Summary of Key Pharmacokinetic Parameters

<i>Linearity/non-linearity</i>	Systemic exposures of obeticholic acid increase dose proportionally (5, 10, or 25 mg once daily for 14 days). Exposures of glycine and taurine conjugates of obeticholic acid and total obeticholic acid increase in a greater than dose-proportional manner.
<i>Steady state</i>	Simulations have indicated a time to steady-state of 2 weeks. ¹
<i>Plasma half-life</i>	~4 d ¹
<i>C_{max}</i>	53.7 (36.86) ng/mL, mean (SD), single dose 10 mg ² 125.5 (53.74) ng/mL, mean (SD), single dose, 25 mg ²
<i>C₂₄</i>	Not determined
<i>AUC</i>	568.1 (409.68) ng·h/mL, mean (SD), single dose, 10 mg ² 1259.7 (645.53) ng·h/mL, mean (SD), single dose, 25 mg ²
<i>Bioavailability</i>	Not determined
<i>Absorption</i>	Coadministration with food does not alter obeticholic acid absorption.
<i>Protein Binding</i>	>99%
<i>Volume of Distribution</i>	618 L
<i>CSF:Plasma ratio</i>	Not determined
<i>Semen:Plasma ratio</i>	Not determined
<i>Renal Clearance</i>	<3%
<i>Renal Impairment</i>	Renal function does not impact obeticholic acid pharmacokinetics.
<i>Hepatic Impairment</i>	Mild hepatic impairment (Child-Pugh Class A) does not impact obeticholic acid pharmacokinetics. Moderate to severe hepatic impairment (Child-Pugh Class B and C) increases the systemic exposure of obeticholic acid and its active conjugates. A modified dose regimen is recommended

Obeticholic acid PK Fact Sheet

Prepared July 2019

Page 2 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Metabolism and Distribution

<i>Metabolised by</i>	Glycine/taurine conjugation in the liver
<i>Inducer of</i>	None reported
<i>Inhibitor of</i>	CYP1A2 (weak)
<i>Transported by</i>	BSEP

References

Unless otherwise stated (see below), information is from:

Ocaliva Summary of Product Characteristics, Intercept Pharma UK & Ireland, March 2018.

Ocaliva Prescribing Information, Intercept Pharmaceuticals Inc., January 2018.

1. Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage, Edwards J, LaCerte C, Peyret T, et al. Clin Transl Sci, 2016, 9(6): 328–336.
2. Ocaliva Product Monograph, Intercept Pharmaceuticals, May 2017.